GC Cell Corp
144510
Company Profile
Business description
GC Cell Corp engages in the provision of anti-cancer immunotherapy. The company is developing an anticancer drug, which is in Phase II clinical trials; and stem cell treatment drugs. It also provides cell banking, sample inspection, clinical trial, and bio logistics services.
Contact
30 beongil to giheung-gu
Gyeonggi
107 Lee Hyun
Yongin16 924
KORT: +82 312609600
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
811
Stocks News & Analysis
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,062.50 | 58.00 | -0.64% |
| CAC 40 | 7,734.84 | 60.06 | 0.78% |
| DAX 40 | 23,807.13 | 210.15 | 0.89% |
| Dow JONES (US) | 45,514.95 | 114.09 | 0.25% |
| FTSE 100 | 9,221.44 | 13.23 | 0.14% |
| HKSE | 25,787.09 | 153.18 | 0.60% |
| NASDAQ | 21,798.70 | 98.31 | 0.45% |
| Nikkei 225 | 43,548.63 | 95.18 | -0.22% |
| NZX 50 Index | 13,253.73 | 27.41 | -0.21% |
| S&P 500 | 6,495.15 | 13.65 | 0.21% |
| S&P/ASX 200 | 8,784.70 | 56.20 | -0.64% |
| SSE Composite Index | 3,800.56 | 26.28 | -0.69% |